Japan’s general trading houses are steadily becoming a force to be reckoned with in the pharmaceutical industry — and not…
ACADEMIA
Nagoya University Concludes Diovan Study Data Trustworthy
Nagoya University concluded in its final report on December 19 that the data and main results of its clinical study involving the hypertension drug Diovan (valsartan) “can be trusted.” The university’s committee on fair research stated in the report that…
To read the full story
Related Article
- MHLW Orders Nagoya Univ. to Probe Corrections Made to Diovan Paper
October 4, 2016
- Nagoya University Denies Diovan Clinical Data Manipulated
December 16, 2013
ACADEMIA
- Japan Sleep Society to Revise Insomnia Guidelines to Reflect Orexin Antagonists
October 8, 2025
- Japan’s Sakaguchi Wins 2025 Nobel Prize in Medicine
October 7, 2025
- Japanese Medical Societies Strongly Recommend COVID Vaccinations from October
September 3, 2025
- Cardiologist Sees Promise in Airwin as First PAH Med to Tackle Disease Progression
September 3, 2025
- Tohoku University Trial Finds Kidney Benefits for Constipation Drug Lubiprostone
September 3, 2025
A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…